{
    "clinical_study": {
        "@rank": "89202", 
        "acronym": "PIPA", 
        "arm_group": [
            {
                "arm_group_label": "Breast Milk", 
                "arm_group_type": "No Intervention", 
                "description": "Breast FED newborns"
            }, 
            {
                "arm_group_label": "Standard Formula", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Standard Formula FED newborns"
            }, 
            {
                "arm_group_label": "Supplemented Formula", 
                "arm_group_type": "Active Comparator", 
                "description": "GOS/PDX Formula FED newborns"
            }
        ], 
        "brief_summary": {
            "textblock": "The study objective is to evaluate whether a specific prebiotic (GOS/PDX) may have an effect\n      in preventing atopic dermatitis, food allergy, intestinal and/or respiratory infections in\n      infants at risk of atopy. In infants with dermatitis, the hypothesis will be tested that\n      prebiotics reduce the severity of the disease."
        }, 
        "brief_title": "Prebiotics in Prevention of Atopy", 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a prospective, double blind, randomised, 24 month study trial  comparing\n      formula with 50/50 mixture of GOS/PDX (Enfamil Premium Infant Formula 1 for children <6\n      months and Formula 2 for children \u2265 6 months) versus standard formula (Enfamil Premium\n      Formula 1 and 2).\n\n      Study population is composed by newborns at risk for allergy that will be identified at time\n      of delivery. Infants will be eligible if at least one parent or one older sibling have a\n      physician-diagnosed atopic disease (asthma, allergic rhinoconjunctivitis  , atopic\n      dermatitis, allergic urticaria, and food allergy as follow described. At time of enrolment\n      (within the first 4 weeks of life) infants will be randomised 1:1 to receive once they will\n      start formula feeding before the day of the 6th month birthday."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Gestational age >37 and < 42 weeks.\n\n          2. Birth weight > 2500 gr.\n\n          3. At risk of atopy (see appendix 1).\n\n          4. Informed consent signed by the parents (see appendix 3).\n\n        Exclusion Criteria:\n\n          1. Congenital immunodeficiency\n\n          2. Severe congenital disorders or malformations\n\n          3. Born to mother with diabet\n\n          4. Long term intake (> 7 consecutive days) of pro- or prebiotics\n\n          5. Children who have already assumed \u2265 50 mL for feeding bottle of Formulas different\n             from the one object of this study for up to a month.\n\n          6. Parents expected not to be compliant with the study procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "24 Weeks", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "380", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116452", 
            "org_study_id": "PIPA"
        }, 
        "intervention": {
            "arm_group_label": "Supplemented Formula", 
            "description": "50:50 mixture of GOS/PDX formula will be administered", 
            "intervention_name": "Supplemented Formula", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Padova", 
                    "country": "Italy", 
                    "zip": "35128"
                }, 
                "name": "University of Padova - Department of Pediatrics"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effects of GOS/PDX Supplemented Formula in Preventing and Modifying the History of Allergy and Acute Infections in a Population of Infants at Risk of Atopy", 
        "overall_official": [
            {
                "affiliation": "University of Naples", 
                "last_name": "Alfredo Guarino, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Padova", 
                "last_name": "Stefania Zanconato, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Cumulative incidence of atopic dermatitis at 36 and 48 weeks", 
            "measure": "Cumulative incidence", 
            "safety_issue": "Yes", 
            "time_frame": "36 - 48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116452"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federico II University", 
            "investigator_full_name": "Alfredo Guarino", 
            "investigator_title": "Head physician of Department of Translational Medical Science", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Severity of atopic dermatitis as judged by the SCORAD score at 36 and 48 weeks and its distribution in three different groups: mild (<15 SCORAD points), moderate (15-40 SCORAD points), and severe (>40 SCORAD points) according to the objective components of the index", 
            "measure": "Severity", 
            "safety_issue": "Yes", 
            "time_frame": "36-48 weeks"
        }, 
        "source": "Federico II University", 
        "sponsors": {
            "collaborator": {
                "agency": "Mead Johnson Nutrition", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Federico II University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2011"
    }
}